Fri, May 2, 2:05 PM (21 days ago)
**Thermo Fisher Scientific Inc. (TMO) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $10.364B (flat YoY) - **Operating Income:** $1.716B (3% YoY growth) - **Operating Margin:** 16.6% (up 0.5% YoY) - **Net Income:** $1.511B (14% YoY growth) - **EPS:** $3.98 (15% YoY growth) - **Cash Flow from Operations:** $723M (down 42% YoY) **Profit Margins:** - **Operating Margin:** 16.6% - **Net Margin:** 14.6% **Cash Flow:** - **Operating Cash Flow:** $723M (down 42% YoY) - **Capital Expenditures:** $362M - **Free Cash Flow:** $373M (down 59% YoY) **Earnings Changes:** - **EPS Growth:** 15% YoY - **Operating Income Growth:** 3% YoY **Quarterly Performance:** - **Revenue Growth:** Flat YoY, driven by pharma and biotech market demand, offset by reduced COVID-19 related products. - **Segment Performance:** Life Sciences Solutions and Analytical Instruments segments showed organic growth, while Laboratory Products and Biopharma Services declined. - **Geographic Performance:** Europe and Asia-Pacific saw sales growth, while North America remained flat. **Trends & Uncertainties:** - **Market Trends:** Increased demand in pharma and biotech, reduced demand for COVID-19 related products. - **Uncertainties:** Economic conditions, regulatory changes, and foreign exchange fluctuations. - **Future Operations:** Continued focus on high-impact innovation, strategic investments, and productivity improvements. **Future Outlook:** - **Pending Acquisition:** Solventum Corporation's Purification & Filtration business for $4.1B, expected to close by end of 2025. - **Capital Deployment:** Focus on mergers and acquisitions, share buybacks, and dividends. - **Liquidity:** Strong cash position and access to capital markets. **Non-GAAP Measures:** - **Adjusted Operating Income:** $2.269B (flat YoY) - **Adjusted Operating Margin:** 21.9% (down 0.1% YoY) - **Adjusted EPS:** $5.15 (1% YoY growth) **Summary:** Thermo Fisher Scientific Inc. (TMO) reported flat revenue growth in Q1 2025, with operating income and net income showing modest growth. The company faced headwinds from reduced demand for COVID-19 related products but saw growth in the pharma and biotech markets. Thermo Fisher remains focused on strategic investments, productivity improvements, and potential acquisitions to drive future growth. The company's strong cash position and access to capital markets provide a solid foundation for continued operations and expansion.